Search results
Results from the WOW.Com Content Network
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. [5] [6] [10] Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
Pembrolizumab (Keytruda, formerly MK-3475 and lambrolizumab) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. In 2017, it became the first immunotherapy drug approved for ...
FDA accepts Merck's (MRK) sBLAs for a six-week dosing schedule of Keytruda for melanoma and multiple other indications Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA Skip to main ...
Lighter Side. Politics. Science & Tech. Sports. Weather. 24/7 Help. ... The Keytruda combo has been approved for two indications related to the treatment of cervical cancer. Cervical cancer, which ...
This makes Keytruda plus chemoradiotherapy the first anti-PD-1-based immunotherapy combination approved in the U.S. as a treatment for newly diagnosed patients with a certain type of cervical ...
The U.S. health regulator's approval extends Keytruda's use in combination with chemotherapy as a treatment given before surgery to shrink the size of the tumor in patients. The U.S. drugmaker is ...
Capmatinib was approved for medical use in the United States in May 2020. [7] [8] Capmatinib is the first therapy approved by the US Food and Drug Administration (FDA) to treat non-small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping). [4]